Abstract 7P
Background
Metastasis accounts for 90% of cancer related deaths and blocking of metastatic cascade has critical clinical impact. However, the clinical drug development for cancer treatment, including cancer immunotherapies, is evaluated largely depending on their ability to cause tumour shrinkage and ignores the effect on metastasis as it has proven challenging to target. Therefore, there is an urgent need for novel therapeutic strategies and agents targeting metastasis. Using an attenuated Salmonella typhimurium strain YB1 engineered by our lab, we have found a potent suppressive effect of attenuated Salmonella on cancer metastasis, regardless of cancer types and genetic background, by evoking strong anti-metastatic immune response.
Methods
Mutant mice and antibody-mediated cell depletion were used to identify the host genetic and cellular requirement for the bacterial supression of cancer cell metastasis. CyTOF (mass cytometry or cytometry by time of flight) was used to investigate the the innate immune responses after Salmonella treatment.
Results
Our studies showed that suppression of cancer metastasis by attenuated Salmonella only requires the innate immune response. Among the many induced cytokines, IFN-γ was identified as an indispensable factor for inhibiting cancer metastasis. CyTOF and antibody-mediated cell depletion analysis of the innate immune responses after Salmonella treatment, revealed that NK cells are the major factor involved in Salmonella-provoked metastasis suppression.
Conclusions
We found that IFN-γ was mainly produced by NK cells during early Salmonella infection, and in turn, IFN-γ promoted the accumulation, activation and cytotoxicity of NK cells. The IFN-γ-dependent NK cells directly eliminated newly accumulated cancer cells in the lung to block the cancer metastasis cascade in response to the Salmonella treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This work was supported by grants from the Shenzhen Peacock Team Project (KQTD2015033117210153) and Shenzhen Science and Technology Innovation Committee Basic Science Research Grant (JCYJ20170413154523577).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09